This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Alamar Biosciences Lists on NASDAQ
Business IPO listing

Alamar Biosciences Lists on NASDAQ

Analysis based on 6 articles · First reported Apr 20, 2026 · Last updated Apr 20, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful Nasdaq-100 listing of Alamar Biosciences, a precision proteomics company, is expected to positively impact the biotechnology and healthcare sectors by bringing advanced diagnostic technologies to market. This event also validates the investment strategy of Live Oak Venture Partners, potentially encouraging further venture capital investment in similar high-growth healthcare technology firms.

Biotechnology Healthcare Venture Capital
Event Summary

Alamar Biosciences, a company specializing in precision proteomics and a portfolio company of Live Oak Venture Partners, successfully listed on the Nasdaq-100 Stock Exchange on April 17th, 2026. The company issued shares at $17, opening at $22.6, resulting in a market capitalization of approximately $1.5 billion. Live Oak Venture Partners, a significant institutional investor, had led Alamar Biosciences' Series A financing in 2020 and continued to support its development through Series B and C rounds, holding about a 19.2% stake before the IPO. Alamar Biosciences, founded in 2018, develops and commercializes proteomics technologies like NULISA™ and the ARGO™ HT system, which are designed for ultra-high sensitivity protein detection and automated workflows, serving over 300 customers across 25 countries.

Entities Involved
priv
Alamar Biosciences
Alamar Biosciences successfully listed on the Nasdaq-100 Stock Exchange, raising its market capitalization to approximately $1.5 billion and enabling further development of its proteomics technologies.
Importance 100.0 Sentiment 75.0
priv
Live Oak Venture Partners
Live Oak Venture Partners, an early investor in Alamar Biosciences, saw its 19.2% stake in the company become publicly traded, validating its investment strategy in the healthcare and technology sectors.
Importance 80.0 Sentiment 60.0
index
Nasdaq-100
Nasdaq-100 served as the exchange for Alamar Biosciences' successful public listing, facilitating the company's entry into the public market.
Importance 50.0 Sentiment 0.0
per
William Mowitt
William Mowitt, Managing Partner of Live Oak Venture Partners, expressed congratulations and confidence in Alamar Biosciences' future impact on precision diagnostics.
Importance 30.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.